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Abstract: β-lactam antibiotics are excellent drugs for treatment of staphylococcal infections, due to
their superior efficacy and safety compared to other drugs. Effectiveness of β-lactams is severely
compromised due to resistance, which is widespread among clinical strains of Staphylococcus aureus.
β-lactams inhibit bacterial cells by binding to penicillin binding proteins (PBPs), which perform the
penultimate steps of bacterial cell wall synthesis. Among PBPs of S. aureus, PBP2a has received the
most attention for the past several decades due to its preeminent role in conferring both high-level and
broad-spectrum resistance to the entire class of β-lactam drugs. Studies on PBP2a have thus unraveled
incredible details of its mechanism of action. We have recently identified that an uncanonical, low
molecular weight PBP of S. aureus, PBP4, can also provide high-level and broad-spectrum resistance
to the entire class of β-lactam drugs at a level similar to that of PBP2a. The role of PBP4 has typically
been considered not so important for β-lactam resistance of S. aureus, and as a result its mode of
action remains largely unknown. In this article, we review our current knowledge of PBP4 mediating
β-lactam resistance in S. aureus.
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1. Introduction
Staphylococcus aureus is an important bacterial pathogen, which causes bloodstream, lower
respiratory tract, and skin and soft tissue infections, inflicting high morbidity and mortality
worldwide [1–3]. Due to its remarkable ability to acquire resistance to antimicrobial agents, a large
number of drugs can’ be currently used to treat S. aureus infections. β-lactam antibiotics remain as
one of the key choices for the treatment of S. aureus infections due to their excellent efficacy and safety.
However, widespread β-lactam resistance among clinical strains of S. aureus limits their use [4].
β-lactams inhibit bacterial cell wall synthesis by binding to Penicillin Binding Proteins (PBPs),
which mediate the penultimate steps of bacterial cell wall synthesis [5]. Resistance to β-lactams in
S. aureus is primarily mediated by two known mechanisms, both of which are horizontally acquired
by the bacteria [1]. Resistance to penicillin, the first β-lactam introduced to the health care settings
is due to β-lactamase, a secreted enzyme that cleaves the β-lactam ring, inherently present in this
group of antibiotics. β-lactamase is encoded by the gene blaZ, which is maintained in a plasmid [6].
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Resistance mediated by β-lactamase is typically narrow spectrum since it can only inactivate penicillin
or drugs that are structurally similar. Currently, a majority of clinical S. aureus strains are β-lactamase
positive and penicillin is rarely used to treat S. aureus infections [2]. Resistance to methicillin, another
iconic β-lactam drug that was introduced to the healthcare system in the 1960s, is due to Penicillin
Binding Protein 2a (PBP2a; also referred as PBP 2′), encoded by the gene mecA or mecC, which
is maintained in the Staphylococcal Chromosomal Cassette element, SCCmec [1,7]. Owing to its
remarkable low affinity (due to slow acylation rate) to methicillin, PBP2a allows bacterial cell wall
synthesis in presence of high concentrations of the drug, which is otherwise detrimental for the
bacteria. Thus, PBP2a provides high-level resistance to methicillin. In addition, resistance mediated
by PBP2a is considered to be broad-spectrum since it provides resistance not only to methicillin but
to the entire β-lactam class of drug [1,5]. PBP2a is present among all Methicillin Resistant S. aureus
(MRSA) strains, which, according to a recent estimate, causes >50% of bacteremia caused by S. aureus
in the USA [8] and is associated with significantly higher health care related costs in the USA [9].
Current treatment of critical S. aureus infections can be carried out by ceftaroline, a highly advanced
β-lactam drug that received FDA approval in 2010. Several recent clinical surveillance studies however
suggest that ceftaroline non-susceptibility in S. aureus is on the rise, which is mainly due to PBP2a
point mutations [10,11].
Control of both the known β-lactam resistance mechanisms is mediated by similar inducible
pathways. When expression of blaZ or mecA are not warranted, their expression is suppressed by
transcriptional repressors, BlaI and MecI respectively. Presence of β-lactam in the bacterial surrounding
is sensed by a set of integral membrane proteins, BlaR1 and MecR1 respectively. Subsequently, BlaR1
and MecR1 undergo a site-specific auto-proteolysis, releasing their intracellular zinc metalloprotease
domain into the bacterial cytosol. The released zinc metalloprotease degrades BlaI or MecI to de-repress
blaZ/mecA expression leading to resistance [12,13]. Owing to the high similarity of the β-lactam
resistance pathways, they are also known to cross regulate each other’s target genes [14,15]. Inducible
expression of β-lactam resistance mediators in this manner ensures timely expenditure of cellular
resources as warranted.
In addition to PBP2a, which is only present in MRSA isolates, every S. aureus strain possess four
other intrinsic, core genome encoded PBPs, PBP1 through 4. Currently, the role of PBP1 through 4 in
β-lactam resistance or cell wall synthesis and how their expression is regulated, remains elusive to
much extent.
2. PBPs in S. aureus and Their Role in Bacterial Physiology and β-Lactam Resistance
PBPs code for membrane associated proteins that perform the penultimate steps of bacterial cell
wall synthesis. They crosslink peptidoglycans, the building block of a bacterial cell wall. β-lactam
antibiotics inactivate PBPs by covalently binding to their active site [16]. Since the cell wall is an
essential component, inhibition of PBPs through β-lactam drugs compromise cell wall synthesis, which
is detrimental to the viability of the bacteria [17,18].
Every S. aureus strain possesses four intrinsic, core genome encoded PBPs (PBP 1 through 4),
whose molecular masses are 85, 81, 75 and 45 kDa respectively [16,19–22]. MRSA strains in addition to
PBP 1 through 4 also possess the horizontally acquired PBP2a, whose molecular mass is 76 kDa. PBP 1
and 2 play essential role/s in bacterial cell viability whereas PBP2a and PBP4 are non-essential, and
as a result genes coding for PBP2a and PBP4 can be deleted from the bacterial genome without any
noticeable change in their survival.
Pertaining to bacterial cell wall synthesis, PBPs perform two major functions through their
transpeptidase (TPase) and transglycosylase (TGase) activities. Through TPase activity, PBPs crosslink
two peptidoglycan units through their penta-glycine cross-bridge, whereas through TGase activity, they
crosslink two peptidoglycan units through their sugar units. Although both functions are important
for cell wall synthesis, it is the TPase activity of PBPs that confers enhanced cell wall cross-linking and
provides structural rigidity to the bacterial cell wall. Every PBP of S. aureus possess TPase activity
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and PBP2 is the only known bi-functional PBP that possesses both TPase and TGase activities [5,23].
For proper cell wall synthesis, both TPase and TGase activities are required and need to be properly
coordinated in a spatial and temporal manner, especially during de-novo cell wall synthesis.
β-lactams specifically inhibit the TPase activity of PBPs at differing affinities [24]. As mentioned
above, PBP2a has low affinity to the entire class of β-lactam antibiotics and is resistant to β-lactam
acylation. Thus, in presence of a high concentration of β-lactams that inactivates TPase activity of other
PBPs, PBP2a continues to be functionally active due to its low β-lactam affinity and maintains proper
cell wall synthesis through its TPase activity [1]. Analysis of the crystal structure of PBP2a suggests
that its active site is hidden in a cleft that is inaccessible to the drugs and thus provides a structural
basis for its low-affinity to β-lactams [25]. Highly advanced 5th generation cephalosporins, such as
ceftaroline, have been designed to access the active site of PBP2a and consequently they are able to
efficiently inhibit PBP2a [26]. Besides PBP2a, other PBPs usually play a less prominent role in β-lactam
resistance. Clinical strains with point mutations in these PBPs have been previously associated with
borderline β-lactam resistance [27–30] and our recent results as mentioned below have shown that
PBP4 can mediate high-level resistance to β-lactams.
In addition to maintaining cell wall synthesis at the cell periphery, PBPs also play a key role in
bacterial cell division through mediating cell wall synthesis at the division septum, which ensures
proper segregation of cellular materials from a mother to its daughter cells. The division septum is
an active site of cell wall synthesis where multiple proteins in addition to PBPs need to structurally
and functionally coordinate. The machinery of S. aureus that maintains cell wall synthesis at the cell
periphery or at the division septum remains poorly characterized. PBP2 (the only bi-functional PBP)
has been shown to co-ordinate with PBP2a and PBP4 to mediate cell wall synthesis but their exact
mode of action remains unknown [23]. In addition to these, PBP1 has been shown to be important for
cell division and septation [31] and PBP3 has been associated with autolysis in S. aureus [32].
3. PBP4 an Uncanonical PBP in S. aureus
PBP4 is roughly half the size of other PBPs and is the only member of Low Molecular Weight
(LMW) PBP in S. aureus. PBP4 is generally expressed in low amounts compared to other PBPs, as its
expression is likely very tightly controlled in S. aureus [19,21,33]. Unlike PBP2a, how PBP4 is regulated
remains unknown. It is speculated that PBP4 mediated TPase activity is important for generation of
highly cross-linked staphylococcal cell wall [23].
In the recent past, elegant work carried out through confocal and epifluorescence microscopy
has demonstrated that PBP4 is localized both at the cell periphery and at the division septum. Due
to its ability to carry out TPase activity onto partially cross-linked peptidoglycan, PBP4 can repair
peptidoglycan defects in cells in a non-de novo manner [34–36]. Although PBP4 has been shown to play
an accessory role in resistance among heterogeneously β-lactam resistant strains of S. aureus [37,38],
a study carried out in the 1990s depicted PBP4 to mediate moderate level resistance to β-lactam
antibiotics [16,39]. We recently identified that PBP4 can mediate high-level and broad-spectrum
β-lactam resistance in S. aureus that is otherwise known to be mediated by PBP2a in S. aureus [33,40].
4. Role of PBP4 in β-Lactam Resistance of S. aureus
We recently discovered an uncanonical mode of high-level β-lactam resistance in our laboratory,
during experiments carried out to investigate resistance mechanisms to new generation cephalosporins
(such as ceftobiprole and ceftaroline) in S. aureus [40–43]. Our results indicate that laboratory passaged
strains of S. aureus that lacked mecA and blaZ, the known mediators of β-lactam resistance, can develop
high-level resistance to new generation cephalosporins. This indicate that factor/s other than mecA
and blaZ were responsible for this newly discovered resistance phenotype.
Similar passaging studies carried out subsequently with two S. aureus strains (COL and SF8300,
strains representing an archaic and USA300 backgrounds respectively) in nafcillin (a close relative of
methicillin) indicate that this mode of resistance is not only restricted to new generation cephalosporins
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or to any particular S. aureus strain. The passaged strains are resistant to the entire class of β-lactam
drugs, which suggests that the underlying basis of resistance is broad spectrum in nature. Furthermore,
the high-level resistance that these strains display is comparable to that mediated by PBP2a [33,40,42,43].
To determine the underlying basis of resistance, genome sequencing was carried out, which
indicated that mutations associated with pbp4 were present in each and every resistant passaged
strains [40,43]. This suggests that pbp4 could play a role in β-lactam resistance of these strains.
Two different types of mutations associated with pbp4 were detected: (a) missense mutations in
pbp4 that surrounded the active site serine (S75) of PBP4 [42,43]; and (b) small deletion, duplication
and point mutations within the pbp4 promoter region [42,43]. While the role of the pbp4 missense
mutations is currently unclear, the pbp4 promoter mutations led to two different phenotypes, PBP4
overproduction and increased cell wall crosslinking [33,40].
A more direct role of PBP4 in mediating high-level β-lactam resistance of these strains came
from subsequent molecular genetic studies [40,42,44]. Deletion of pbp4 and substitution of its active
site serine to functionally inert alanine (S75A) turned resistant strains completely susceptible, while
complementation of pbp4 restored resistance, indicating that PBP4 played a quintessential role in
resistance of these strains. Further evidence of a pivotal role of PBP4 in this mode of resistance came
from subsequent experiments, which showed that S. aureus strains that lack both mecA and pbp4 are
unable to develop resistance upon similar passaging in the β-lactam drug [42].
To determine the role of each kind of pbp4 mutation (i.e., missense and promoter mutations
associated with pbp4) in β-lactam resistance, isogenic mutant strains were created by reconstituting
the pbp4 missense and promoter mutations individually and together in a wild type S. aureus strains
lacking mecA and blaZ [44]. Results of resistance assays revealed that pbp4 missense mutations alone
did not play a big role in resistance whereas pbp4 promoter mutation conferred significant amount of
β-lactam resistance when compared to their isogenic wild type strain. Interestingly, pbp4 missense
and promoter mutations together provided a synergistic effect on β-lactam resistance, which indicated
that the missense mutations indeed play a role in resistance but how this is achieved is unclear at this
point [44].
Clinical significance of PBP4-mediated resistance was unknown until recently. Recent clinical
surveillance studies carried out by Argudín et al. detected pbp4 associated mutations (both missense
mutations that targeted its catalytic site and promoter mutations) in clinical strains of S. aureus that
are either non-susceptible or resistant to β-lactam drugs [27,28]. Interestingly these mutations were
detected in both MRSA and MSSA strains suggesting that pbp4 mediated β-lactam resistance might
have been underappreciated clinically in the past and needs to be investigated further.
5. Outlook/Future Directions
The role of PBP4 in bacterial cell wall synthesis and β-lactam resistance is currently
emerging. Identification of clinically resistant strains bearing similar pbp4 mutations detected among
laboratory-passaged strains underscores its importance and urges further investigation to define
the mechanistic basis of this mode of β-lactam resistance in S. aureus. Studies carried out thus far
have indicated that PBP4 could play an important role in β-lactam resistance through mutations in
its gene and promoter. The pbp4 promoter mutations lead to PBP4 overproduction, which in turn
facilitates enhanced crosslinking of the bacterial cell wall. Although it is currently unknown how
PBP4 missense mutations mediate β-lactam resistance, our results indicate that they do indeed play a
role in resistance [44]. Currently, ongoing crystal structure and biochemical analysis of mutant PBP4
(i.e., PBP4 with missense mutations) will shed more light onto how they mediate resistance in the
near future. In addition to this, future studies are needed to determine the regulatory basis of pbp4
expression, as PBP4 overproduction happens to be an effective way to achieve β-lactam resistance
in S. aureus. PBP4 being a mono-functional PBP that possesses only TPase activity and since for
effective cell wall synthesis, both TPase and TGase activities are required, suggests that PBP4 mediated
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enhanced crosslinking of bacterial cell wall has to be coordinated with the function of PBP2 (only PBP
that possess TGase activity in S. aureus).
Previous studies have shown that PBP2 interacts with PBP4 during cell wall synthesis [23]. It will
thus be interesting to determine how pbp4 associated mutations affect the PBP4-PBP2 interaction.
It is important to note here that many of our resistant passaged strains as well as the recently
identified clinical strains possesses pbp2 mutations in addition to that in pbp4. It is possible that
these mutations can promote a more effective PBP4-PBP2 interaction or functional co-ordination.
Finally, yet importantly, given the fact that bacterial cell wall is an important component that can be
recognized by host cells to elicit an antibacterial response it will be interesting to determine how highly
cross-linked cell wall of our resistant strains coordinate a host cell response. Knowledge gained from
these studies in the near future will not only enhance our knowledge about this uncanonical mode of
β-lactam resistance, but also about the basic biology of how PBP4 functions, its interacting partners,
its regulatory basis and how it modulates host cell response.
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